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Natural killer cells modulate motor neuron-immune
cell cross talk in models of Amyotrophic Lateral
Sclerosis
Stefano Garofalo1✉, Germana Cocozza2, Alessandra Porzia3, Maurizio Inghilleri 4, Marcello Raspa5,
Ferdinando Scavizzi 5, Eleonora Aronica6, Giovanni Bernardini 7, Ling Peng 8, Richard M. Ransohoff9,
Angela Santoni2,7 & Cristina Limatola 2,10✉
In amyotrophic lateral sclerosis (ALS), immune cells and glia contribute to motor neuron
(MN) degeneration. We report the presence of NK cells in post-mortem ALS motor cortex
and spinal cord tissues, and the expression of NKG2D ligands on MNs. Using a mouse model
of familial-ALS, hSOD1G93A, we demonstrate NK cell accumulation in the motor cortex and
spinal cord, with an early CCL2-dependent peak. NK cell depletion reduces the pace of MN
degeneration, delays motor impairment and increases survival. This is confirmed in another
ALS mouse model, TDP43A315T. NK cells are neurotoxic to hSOD1G93A MNs which express
NKG2D ligands, while IFNγ produced by NK cells instructs microglia toward an inflammatory
phenotype, and impairs FOXP3+/Treg cell infiltration in the spinal cord of hSOD1G93A mice.
Together, these data suggest a role of NK cells in determining the onset and progression of
MN degeneration in ALS, and in modulating Treg recruitment and microglia phenotype.
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Amyotrophic Lateral Sclerosis (ALS) is a fatal neurode-generative disease characterized by the progressivedegeneration of motor neurons (MN)1. In a subgroup of
familial ALS (fALS), mutant superoxide dismutase 1 (SOD1) is
expressed. In this form of ALS and in the corresponding mouse
models, microglia acquire an inflammatory phenotype, affecting
MN death2,3, and myeloid cells expressing mutated SOD1 pro-
mote neurotoxicity4,5. As in other CNS disorders, microglia exert
protective or detrimental functions in different disease phases,
depending on cell-autonomous features and local microenviron-
mental cues6–8. As one example, the expression level of mutant
SOD1 in microglia correlates with the late phase of disease5,
while microglial phenotypes in hSOD1G93A mice are modulated
by infiltrating Treg cells, through cytokine production4,9.
Moreover, Treg number and FOXP3 expression are reduced in
rapidly progressing ALS patients, and it has been shown that
the passive transfer of Tregs prolongs survival, suppressing
neuroinflammation10.
NK cells regulate both the adaptive and innate immune
responses, and CNS infiltrating NK cells modulate neuroin-
flammation in neurodegenerative diseases11–14, and affect
microglial phenotype in cerebral tumors15,16. In addition, it was
recently described that in pathological conditions, damaged
neurons express NKG2D ligands and selectively succumb to NK
cell-mediated degeneration17. Previous longitudinal cohort stu-
dies of peripheral blood from ALS patients revealed an increased
number of NK cells in patients18; additionally, end-stage
hSOD1G93A mice showed high NK cell frequency in the spinal
cord19.
Here, we investigate the functional role of NK cells in disease
onset and progression in the hSOD1G93A mice. We found that
NK cells directly kill spinal cord motor neurons in a NKG2D-
dependent manner. In addition, we characterized NK cell cross
talk with both resident microglia and infiltrating Treg cells in the
hSOD1G93A mice. We propose that these communication
mechanisms orchestrate a vicious cycle of inflammatory signals
contributing to onset of motor impairment but not disease
progression. Given NK cell presence in postmortem sALS motor
cortex and spinal cord, and the expression of NKG2D ligands on
postmortem sALS motor neurons, these data suggest a key role of
NK cells in ALS onset, highlighting the importance of immune
cells in motor neuron loss.
Results
NK cell analyses in ALS patients. To determine whether NK cells
were altered in ALS patients (Tables 1, 2), we analysed the CNS
tissues and blood of sporadic ALS patients (sALS) for NK cell
presence and for frequency of NK cell subtypes. NKp46+ cells
were detected in sALS spinal cord and cerebral motor cortex
postmortem tissues while they were not observed in the spinal
cord or motor cortex of controls (patients listed in Table 1,
Fig. 1a). In addition, peripheral blood from sALS patients showed
a reduction of circulating CD56+/CD3− cells, both in the
CD56high and CD56low cell populations, in comparison with
controls (patients listed in Table 2, Fig. 1b).
NK cells infiltrate motor cortex and spinal cord of hSOD1G93A
mice. We then investigated the time dependency of NK cell
infiltration in the CNS of hSOD1G93A mice. Data in Fig. 2a show
that NK cells were present in the spinal cord and motor cortex of
hSOD1G93A mice, with a peak at the early phase (10–13 weeks),
and a decline during the period of motor impairment
(16–19 weeks). NKp46+ cells were absent in these same CNS
regions of wild-type (wt) mice and were not observed in other
regions (i.e. hippocampus, striatum and cortex) of the CNS in
hSOD1G93A mice (Supplementary Fig. 1a shows a representative
striatal region). NK cells isolated from the spleen and the spinal
cord of wt and hSOD1G93A mice were analysed for the expression
of activation markers and cytotoxic factors CD69, Granzyme b
(GZMb) and perforin (PRF). The NK cells infiltrated in the CNS
of hSOD1G93A mice showed higher frequency of GZMb and
CD69, while no differences were observed in frequency and
marker expression on NK cells isolated from the spleen of wt and
Table 1 List of patients for NK cell staining in slices.
Patients Clinical diagnosis Gender Site of onset Age Disease duration
(months)
C9orf72 repeat expansion FUS and
SOD1 mutation, TDP43 pathology
1 sALS M Spinal 53 33 C9orf72, TDP43
2 sALS M Bulbar 58 11 TDP43
3 sALS M Spinal 66 22 TDP43
4 sALS F Spinal 64 34 C9orf72, TDP43
5 sALS M Spinal 53 33 C9orf72, TDP43
6 sALS F Bulbar 74 31 C9orf72, TDP43
7 sALS F Bulbar 66 35 TDP43
8 sALS M Spinal 68 12 TDP43
9 sALS M Spinal 69 24 TDP43
10 sALS F Bulbar 65 24 TDP43
11 sALS M Bulbar 40 35 TDP43
12 sALS M Spinal 71 33 TDP43
1 Control M n/a 54 n/a –
2 Control M n/a 56 n/a –
3 Control F n/a 66 n/a –
4 Control F n/a 79 n/a –
5 Control F n/a 35 n/a –
6 Control M n/a 49 n/a –
7 Control M n/a 75 n/a –
8 Control M n/a 74 n/a –
Site of onset (region in which first symptoms occurred): bulbar onset, spinal onset. Age: years. Disease duration: time from diagnosis until death in months. Fused in sarcoma/translocated in liposarcoma
(FUS), chromosome 9 open reading frame 72 (C9orf72). The postmortem delay for ALS patients and controls was of 8 ± 2 h.
ALS Amyotrophic lateral sclerosis, sALS sporadic ALS, M male, F female, n/a not applicable.
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hSOD1G93A mice (Fig. 2b, c); PRF was expressed in all the NK
cells. To better characterize the position of NK cells in the CNS,
relative to vessels, we calculated the mean distance of NKp46+
cells from CD31+ (endothelial) cells, that was 152 ± 29 μm
(Fig. 2d), indicating that many NK cells observed were not in
proximity of vessels (i.e. perivascular) but entered the brain
parenchyma. Since the involvement of adaptive immune response
in ALS is debated20, we also investigated the infiltrating lym-
phocyte populations. Spinal cord and motor cortex of
hSOD1G93A mice showed increased accumulation of CD19+ B
cells, CD8+ and CD4+ T cells, with a time dependent reduction
of CD8+ T cells at later stages (Supplementary Fig. 1b). To
identify possible chemotactic signals involved in NK cell
recruitment, we focused our attention on CCL2, a chemokine
whose expression increases both in ALS patients and in
hSOD1G93A mice21 and plays a major role in NK cell recruit-
ment14. At this aim, hSOD1G93A mice were treated (i.p.) with a
CCL2 blocking antibody (Ab-CCL2) and data reported in Fig. 2e
show that Ab-CCL2 treated mice had a significant reduction of
NK cells in the CNS at early disease stages. In addition, Ab-CCL2
treatment decreased the number of CD11b+ myeloid cells (motor
cortex: Veh 1099 ± 134; Ab-CCL2 341 ± 120; spinal cord: Veh
2169 ± 271; Ab-CCL2 460 ± 132. n= 2–6 mice per condition),
and the number of CD3+ cells infiltrating the CNS in hSOD1G93A
mice (motor cortex: Veh 53 ± 26.3; Ab-CCL2 2.7 ± 1.2; spinal
cord: Veh 22.3 ± 7.8; Ab-CCL2 4 ± 1.3. n= 3–6 mice per condi-
tion). These low numbers hampered further subpopulation ana-
lysis. These results demonstrate that NK cells populating the CNS
affected regions of hSOD1G93A mice are recruited to the brain by
CCL2, directly or through other cell recruitment.
NK cell depletion increases survival in mouse models of ALS
hSOD1G93A and TDP43A315T. To assess the possible role of NK
cells in disease onset and progression, we also used another
animal model, the TDP43A315T mice, which express a mutated
TAR-DNA binding protein, accumulate pathologic aggregates of
ubiquitinated proteins in specific neurons, and activate local
astrocytes and microglia, with the loss of both upper and lower
motor neurons22. We treated 8-week-old hSOD1G93A and
TDP43A315T mice with an antibody against NK1.1, to deplete the
NK cell population (see scheme in Fig. 2f). The efficacy of this
treatment in depleting the NK cell (CD3+/NK1.1−) population
was already shown23, and preliminarily confirmed in these new
experiments. hSOD1G93A and TDP43A315T mice depleted from
NK cells showed a delay in onset of motor impairment and an
increase in mean survival time in comparison with vehicle-treated
mice (Fig. 2g), a delay in the onset of the paralysis (in hSOD1G93A
mice, Fig. 2h), with no effect on disease progression. The timing
of NK cell depletion is crucial, because when NK1.1 treatment of
hSOD1G93A mice started at 13 weeks of age, no effects on survival
time was observed (hSOD1G93A vehicle: 139.8 ± 1.9 days, n= 5;
Ab-NK1.1: 136.8 ± 1.6 days, n= 4), in accordance with another
study24. Behavioural tests to evaluate the changes in muscle
strength and motor coordination show that NK cell-depleted
mice preserved motor functions for a longer time, with no
gender-related differences (Supplementary Fig. 2a, b). These
results demonstrate the involvement of NK cells in the onset of
motor signs and survival in two different mouse models of fALS,
without effect on disease progression.
NK cell depletion did not alter the accumulation of CD4+ and
CD8+ T cells either in motor cortex or spinal cord of hSOD1G93A
mice (Supplementary Fig. 2c), so we can exclude that the
observed effects are due to altered infiltration of these T cells.
NK cells exert cytotoxic function against MNs in ALS. To
investigate the mechanisms of NK cell contribution to motor sign
progression, we assayed their cytotoxic function in hSOD1G93A
mice. We first analysed NKG2D ligands (mult-1 and rae-1) and
DNAM-1 (DNAX Accessory Molecule-1) ligands (nectin-2 and
pvr) expression in the spinal cord and motor cortex of
hSOD1G93A mice: data in Fig. 3a, b show that Smi32+ (a neu-
ronal marker of neurofilament H) cells in the spinal cord co-stain
with a murine ligand for NKG2D, Mult-1, only in hSOD1G93A
and not in wt mice. In accordance, qRT-PCR analysis revealed
that neurons (NeuN+ cells), sorted from the spinal cord of
hSOD1G93A mice, overexpressed mult-1 and nectin-2 but not rae-
1 and pvr, in comparison with wt neurons (Fig. 3c). This selective
overexpression may reflect the functional redundancy of NKG2D
and DNAM-1 ligands25. Since NKG2D ligands are involved in
triggering the cytotoxicity of NKG2D receptor-expressing NK
cells, we performed a cytotoxic assay with primary neuronal
cultures obtained from the lumbar region of the spinal cord of 13-
week-old (early phase) hSOD1G93A and wt mice using, as effector
cells, NK cells isolated from the spleen of wt mice (Fig. 3d). We
first demonstrated that, also in primary cultures, hSOD1G93A
Smi32+ cells exhibited an increased expression of Mult-1 protein,
which was absent in primary wt cultures (Supplementary Fig. 3a).
Co-incubation of wt NK cells with primary spinal hSOD1G93A
neurons resulted in an increased percentage of CD107a+
(a lysosomal marker of active degranulation) NK cells, in com-
parison with wt neurons, across a variety of ratios (Fig. 3d and
Supplementary Fig. 3b). Consistently, exposure to NK cells only
affected the viability of hSOD1G93A neurons, not of wt neurons
(Fig. 3d and Supplementary Fig. 3b).
To investigate whether the expression of mutated hSOD
affected NK cell functionality, NK cells isolated from the spleen of
hSOD1G93A mice were tested for cytotoxicity against neurons.
The data shown in Supplementary Fig. 3c indicated that
hSOD1G93A NK cells exhibited similar cytotoxic activity against
wt or hSOD1G93A neurons, as shown for wt NK cells. To
determine the involvement of NKG2D in the neurotoxic activity
of NK cells, NK cell-neuron co-culture experiments were
performed in the presence of anti-NKG2D blocking antibody;
under these conditions the NK cell-mediated cytotoxic activity on
Table 2 List of patients for peripheral blood NK cell
analyses.
Patients Clinical
diagnosis
Gender Site of
onset
Disease
duration
Score
1 sALS F Spinal 18 C
2 sALS M Spinal 9 A
3 sALS F Spinal 16 A
4 sALS M Bulbar 7 C
5 sALS F Spinal 98 B
6 sALS M Bulbar 8 A
7 sALS F Spinal 39 C
8 sALS M Bulbar 44 C
9 sALS M Bulbar 22 C
10 sALS F Spinal 24 A
11 sALS M Spinal 25 B
12 sALS M Spinal 50 C
14 sALS M Bulbar 16 B
15 sALS F Bulbar 12 C
Site of onset (region in which first symptoms occurred): bulbar onset, spinal onset.
ALS Amyotrophic lateral sclerosis, sALS sporadic ALS, M male, F female.
Disease duration: months from diagnosis to blood sample. Score: ALS patient deficit was scored
according to the following scale: A—moderate; B—medium-severe; C—severe; D—complete.
The age of ALS patients was 58.37 ± 3.2 years. Healthy donors were recruited between 50.26 ±
10.2 years, of different gender (n= 14).
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neurons was abolished (Fig. 3d). We then investigated the
molecular mechanisms involved in the neurotoxic activity of NK
cells, interfering with specific stages of lysosome exocytosis. At
this aim we performed in vitro neurotoxicity assay in the presence
of dynasore (dynamin inhibitor) or wiskostatin (N-WASP
inhibitor). Both dynamin and N-WASP inhibition abolished
NK cells-mediated hSOD1G93A neuron death (Fig. 3d). To
evaluate the role of perforin in the lytic activity, NK cells isolated
from prf1 ko mice were incubated, in a cytotoxicity assay, with wt
or hSOD1G93A neurons. Results shown in Fig. 3d demonstrated
that the absence of perforin abolished NK cells-mediated
hSOD1G93A neuron death.
To further investigate in vivo the possible cytotoxic activity of
NK cells against MNs, we verified the presence of potential
physical contacts between NK cells and MNs in the spinal cord of
hSOD1G93A mice, as shown in Fig. 3e. We then analysed the
viability of MNs in the ventral horns of the lumbar spinal cord of
hSOD1G93A mice and observed a reduction of their number in
comparison with wt mice, already at 13 weeks (Fig. 3f). This effect
was attenuated in NK cell-depleted hSOD1G93A mice, where a
higher number of MNs (Smi32+ and ChAT+ cells) was observed,
in comparison with vehicle-treated hSOD1G93A mice (Fig. 3f and
Supplementary Fig. 3d). At later stages (16 weeks), the spinal cord
of NK cell-depleted hSOD1G93A mice showed the same number
of MNs, as compared with vehicle-treated hSOD1G93A mice,
indicating that the effect of NK cell depletion has a limited time
window of efficacy (Supplementary Fig. 3e). Similar results were
observed in male hSOD1G93A mice soon after disease onset
(Supplementary Fig. 3f). The role of NKG2D in NK cell-mediated
MN death was further demonstrated knocking down NKG2D,
treating mice with dendrimers-loaded with NKG2D-specific
siRNA. The efficacy of siRNA silencing was verified in vitro on
human and murine NK cells: Supplementary Fig. 4a shows siRNA
uptake by NK cells after 48 h and the effects on klrk1 gene and
NKG2D protein expression is shown in Supplementary Fig. 4b, c.
Functionally, dendrimer-siRNA NKG2D-transfected NK cells
have a reduced cytotoxic activity against the murine tumour cells
GL261 (Supplementary Fig. 4d). In vivo, in hSOD1G93A mice,
siRNA treatment reduced the circulating NKG2D+ NK cells by
26% ± 5.5%, and silenced NKG2D expression (MFI) by 29% ±
5.5% in cells that remained NKG2D-positive (Supplementary
Fig. 4e). Motor neuron count, in the spinal cord of siRNA-loaded
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Fig. 1 NK cells infiltrate the CNS affected regions in ALS patients. a NKp46+ cells (in red) in slices of the spinal cord and motor cortex obtained from
sALS patients, not present in control patients. 3d reconstruction of one representative NK cell on the right. Scale bar: 20 μm. (n= 8 controls, 12 sALS
patients **P < 0.01 power 0.999 two-tailed Student’s t-test). Each dot represents the number of NKp46+ cells per patient. Only 3 representative black
squares are reported in the graph for Controls, in which were no detected NK cells. b Percentage of CD56+/high/low/CD3− cells obtained from peripheral
blood of control or sALS patients (n= 14 controls, 15 sALS patients. **P < 0.01 power 0.860 two-tailed Student’s t-test). Each dot represents the % of NK
cells per patient. Error bars show mean ± SEM. Source data are provided as a Source Data file.
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dendrimer-treated mice, revealed increased numbers in compar-
ison with empty or scrambled siRNA-dendrimer-treated mice
(Fig. 3f).
Taken together, these data demonstrate the cytotoxic activity of
NK cells against motor neurons expressing NKG2D ligands in the
hSOD1G93A mouse model.
NK cell depletion induces a protective microglia phenotype.
We previously demonstrated that NK cells modulate microglia
phenotype in the context of glioma16. To investigate the possible
cross talk between NK cells and microglia in hSOD1G93A mice,
we analysed the microglia phenotype upon NK cell depletion. To
this end, we analysed Iba+ (a microglia/macrophage marker26)
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cells in spinal cord tissue by two-photon microscopy, measuring
cellular branching and the total area covered by the single cells.
Our data show that hSOD1G93A microglia, in NK cell-depleted
mice, have reduced soma area, increased length of branches and,
in general, cover a wider parenchymal region, compared to
hSOD1G93A microglia from vehicle-treated mice (Fig. 4a).
Moreover, NK cell-depleted hSOD1G93A mice had less Iba1+
cells, in the ventral horns of the spinal cord (Fig. 4b). To further
study NK cell-microglial communication, we isolated microglial
cells from the spinal cord of wt and hSOD1G93A mice, treated
with Ab-NK1.1 or vehicle at 13 or 16 weeks and analysed the
expression of a number of genes that characterize microglia
phenotype in ALS22. Microglia from hSOD1G93A mice pre-
ferentially expressed genes involved in inflammatory micro-
environment, including il-6, il-1β, tnf-α and nos2 (Fig. 4c) and
ROS production (nox2, p47phox) (Fig. 4d). In NK cell-depleted
hSOD1G93A mice, the expression of these genes was significantly
reduced (Fig. 4c, d), with the simultaneous increase of expression
of the anti-inflammatory markers chil3, arg-1, and tgfβ, of the
ROS scavenger msod1 (Fig. 4e, f) and the modulation of other
genes associated with a homeostatic neuroprotective microglial
phenotype (p2yr12, trem2, kcnn4, bdnf, il-15) (Fig. 4g). We did
not observe gender differences in these experiments (Supple-
mentary Fig. 5a) and no alteration in hsod1 expression was
observed (hSOD1G93A vehicle: 1 ± 0.34; Ab-NK1.1: 0.87 ± 0.09;
n= 5). At late-stage disease, microglia isolated from NK cell-
depleted hSOD1G93A mice showed only minor differences in gene
expression as compared with untreated hSOD1G93A mice (il-6,
arg1 and bdnf Supplementary Fig. 5b).
IFNγ mediates NK cell activities in ALS. Investigating the
potential mediators of NK cell effects in ALS, we focused our
attention on IFNγ produced by NK cells. We compared the
expression level of IFNγ in the spinal cord of hSOD1G93A and wt
mice, and detected higher levels of IFNγ in hSOD1G93A, in
comparison with wt mice (Fig. 5a); NK cell depletion significantly
reduced the cytokine levels (Fig. 5a). In accordance, in
hSOD1G93A mice, the frequency of NK cells infiltrating in the
spinal cord and expressing IFNγ was 14.25% ± 2.68% (Fig. 5b)
higher than what reported in brain tumour16. To investigate the
possible relevance of IFNγ produced by NK cells, we treated mice
with the IFNγ-blocking antibody XMG1.2 (see scheme in Fig. 5c).
The efficacy of XMG1.2 treatment was previously shown in
mouse brain16, and was verified in the spinal cord by MHCII
expression analysis in microglia and antibody staining (Supple-
mentary Fig. 6a, b).
We observed that IFNγ immunodepletion increased the mean
survival time of hSOD1G93A mice (Fig. 5d) and delayed paralysis
onset (Fig. 5e) without affecting disease progression. Mice were
longitudinally evaluated for muscle strength, locomotor activity
and motor coordination: IFNγ-depleted mice showed better score
in the hindlimb extension reflex, in the inverted grid and in the
Rotarod tests (Supplementary Fig. 6c). Blocking IFNγ had
consequences similar to NK cell depletion on microglial
phenotype, modulating inflammatory gene expression (Fig. 5f,g).
Since IFNγ stimulates the neuronal release of CCL227 which in
our mouse model contributes to NK cell accumulation in the CNS
(shown in Fig. 2e), we investigated the neuronal expression of ccl2
in NeuN+ cells isolated from the spinal cord of hSOD1G93A mice,
and observed an increased expression in comparison with wt
(Fig. 5h). The expression of ccl2 in NeuN+ cells was abolished in
neurons isolated from the spinal cord of NK cell- and IFNγ-
depleted hSOD1G93A mice (Fig. 5h). At difference, microglial ccl2
expression increased in NK cell-depleted hSOD1G93A mice
compared to vehicle hSOD1G93A and wt mice (Fig. 5i).
NK cells and IFNγ affect Treg number in hSOD1G93A mice.
IFNγ has a crucial role in driving regulatory T cell (Tregs) dif-
ferentiation and proliferation28 and Treg become reduced and
dysfunctional in ALS patients10. We performed an immuno-
fluorescence analysis of FOXP3+ cells (Treg cells) in the spinal
cord of NK cells-depleted hSOD1G93A mice and observed an
increased number of FOXP3+ cells in comparison with control
mice (Fig. 6a). This was confirmed by mRNA analysis, where
foxp3 expression, in the spinal cord of hSOD1G93A mice, was
significantly increased upon NK cell depletion (Fig. 6b). In line
with these results, blocking IFNγ also increased foxp3 expression
demonstrating the role of this cytokine in suppressing Treg cells
in hSOD1G93A mice (Fig. 6b).
NK cell-motor neuron interactions in ALS patients. To inves-
tigate the possible interaction among MNs and NK cells also in
humans, we determined the expression of NKG2D ligands in the
spinal cord and the cerebral motor cortex MNs of sALS patients
and found immunoreactivity for UL16 binding protein 3
(ULBP3), which colocalized with Smi32+ cells and was completely
absent in controls (Fig. 7a, b). Furthermore, Fig. 7c shows the
occurrence of physical contacts between NK cells and MNs in the
spinal cord of ALS patients. In these same tissues, the mean distance
of NKp46+ cells from vessels (CD31+ cells) is 188 ± 43 μm,
Fig. 7d), indicating cells in brain parenchyma. Similarly to what
observed in hSOD1G93A mice, higher IFNγ levels were detected in
the spinal cord of sALS patients in comparison with controls
(Fig. 7e), and more IFNγ+ NK cells were present in the peripheral
blood (Fig. 7f). On the other hand, no differences were detected in
the cytotoxic activity of NK cells isolated from the peripheral
Fig. 2 NK cells infiltrate the CNS and affect survival time in ALS models. a Left: NKp46+ cells (in red) in cerebral slices of the lumbar spinal cord and
motor cortex of hSOD1G93A mice (13 weeks), not present in wt mice. Scale bar: 10 μm. 3d reconstruction of one representative NK cell on the right. Right:
time course analysis of NK1.1+/CD3− cells in the lumbar spinal cord and the cerebral motor cortex of hSOD1G93A mice (mice at 8 and 19 weeks, n= 4;
mice at 10, 13 and 16 weeks, n= 6. **P < 0.01, power 0.999, one-way ANOVA vs 8 weeks). b Frequency of NK1.1+/CD3− cells in the spleen of wt and
hSOD1G93A mice (wt, n= 5; hSOD1G93A n= 8). c Expression of GZMb, PRF and CD69 in the spleen and spinal cord of wt and hSOD1G93A mice (wt, n= 3;
hSOD1G93A, n= 5, **P < 0.01, power 0.841, one-way ANOVA). d Distances of NKp46+ cells from vessel endothelial cells (CD31+ cells) in the spinal cord
of hSOD1G93A (13 weeks) mice (n= 4 mice/21 cells). Scale bar: 20 μm. Representative immunofluorescence is shown. e NK1.1+/CD3− cells frequency in
the motor cortex (top) and in the spinal cord (bottom) of hSOD1G93A mice treated with Ab-CCL2 (n= 6, *P < 0.05 power 0.916 two-tailed Student’s
t-test). Representative density plots are shown on the right. f Scheme of Ab-NK1.1 administration. g Kaplan–Meier curve of hSOD1G93A and TDP43A315T
mice treated with vehicle or Ab-NK1.1 (hSOD1G93A, vehicle: 136.8 ± 1.7 days; Ab-NK1.1: 147.2 ± 2.4 days; n= 5. TDP43A315T, vehicle: 78.5 ± 1.5 days; Ab-
NK1.1: 88.7 ± 1.9 days, n= 4. Data are the mean ± s.e.m. **P < 0.01, two-sided log-rank test). h Age of paralysis, calculated as the absence of hindlimb
movement, upon Ab-NK1.1 treatment in hSOD1G93A mice; vehicle: 18.3 ± 0.2 weeks; Ab-NK1.1: 19.5 ± 0.2 weeks (n= 7, data are the mean ± s.e.m.
**P < 0.01 power 0.921 two-tailed Student’s t-test). For boxplots (a, c, e), the center line, boxes and whiskers represent the median, inner quartiles, and
rest of the data distribution, respectively.
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blood of sALS patients and controls, seen as CD107a expression
upon interaction with NK-susceptible tumor (K562) target cells
(Fig. 7g), and also the expression of GZMb and PRF did not differ
(Fig. 7h, i).
Discussion
We identified a new potential mechanism to explain the non-
cell-autonomous motor neuron degeneration which occurs in
ALS. We demonstrated that, in sALS patients and in the mouse
c
0
1
2
3
4
5
6
m
ul
t-
1 
(f
ol
d 
in
cr
ea
se
)
wt
0
1
2
3
4
5
6
ra
e-
1 
(f
ol
d 
in
cr
ea
se
)
**
0
4
8
12
16
ne
ct
in
-2
 (
fo
ld
 in
cr
ea
se
)
0
1
2
3
4
5
 p
vr
 (
fo
ld
 in
cr
ea
se
)
hSOD1G93A*
Hoechst Smi32 Mult-1 Merge
w
t
1
D
O
Sh
G
93
A
a
)
3
D
C/
1. 1
K
Nf o
%(
701
D
C
+ a
+
-
d
0
20
40
60
80
100
120
140
)
Cfo
%(
reb
munll e
C
C 
e
wt - IgG hSOD1      - IgGG93A hSOD1      - Ab NK1.1G93A
Smi32f
0
2
4
6
8
10
12s
n
or
u
e
n
r
ot
o
m
f
o
r
e
b
m
u
N
**
**
**
wt IgG
hSOD1      IgGG93A
hSOD1      Ab-NK1.1G93A
Smi32
NKp46
NK cells
Neurons
wt 
hSOD1G93A
0
1
2
3
4
5
NK:MN 2.5:1
wt - AbNKG2D
hSOD1      - AbNKG2DG93A ****
hSOD1      empty-DG93A
hSOD1      siRNA NKG2D-DG93A
**
Dynasore
Wiskostatin
C NK:MN 2.5:1
0
20
40
60
80
100
%
 C
ol
oc
al
iz
at
io
n 
sm
i3
2/
m
ul
t-
1
b
hSOD1G93Awt
hSOD1      scrambled siRNA-DG93A
**
wt-MNs hSOD1      -MNsG93A
NK cell PRF-/-
hSOD1      scrambled siRNA-DG93A hSOD1      - siRNA NKG2D-DG93AhSOD1      empty-DG93A
**
**
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15644-8 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1773 | https://doi.org/10.1038/s41467-020-15644-8 |www.nature.com/naturecommunications 7
model hSOD1G93A, NK cells infiltrate the CNS affected regions.
We observed that NeuN+ cells from the spinal cord of
hSOD1G93A mice expressed increased levels of the chemokine
CCL2, and that CCL2 neutralization reduced CNS infiltration
by NK cells. In addition, NK cell depletion increased survival in
hSOD1G93A and TDP43A315T mice and modulated the activa-
tion of microglia and the infiltration of Treg cells in
hSOD1G93A mice. Finally, we reported that both motor neurons
of ALS patients and those of the hSOD1G93A mice express
higher level of NK2GD ligands, important for NK cell cytotoxic
activity. These observations support the knowledge of ALS as a
non-cell-autonomous disease, where motor neuron degenera-
tion results from communication defects with immune and
glial cells.
Previous reports have described that NK cells are present in the
spinal cord of end-stage mSOD1 mice29, and increased NK cell
number is reported in the blood of ALS patients10. At difference,
we considered the relative amount of NK cells with respect to
other populations of PBMC and demonstrated that the frequency
of NK cells in peripheral blood of ALS patients is reduced. Even if
a direct relation among NK cells number and their frequency is
not obvious, further experiments should be performed to estab-
lish possible correlations with disease stage at the moment of
blood collection, also considering ongoing pharmacological
therapies. However, the function of NK cells in disease progres-
sion had never been addressed. We demonstrated that NK cell
recruitment in the CNS of hSOD1G93A mice is CCL2-dependent;
however, we cannot discriminate among a direct effect of CCL2
on NK cells and an indirect effect, coordinating the recruitment
of other cells30 (such as monocytes) and the production of
additional chemoattractant (such as CX3CL1)12,13. The neuronal
production of CCL2 has been associated with neuronal injury in
different models of trauma, pain or viral infection31–33, and CCL2
level increases in the spinal cord tissue of SOD1G93A mice29,30.
These data identify CCL2 as an early damage signal of neural
tissue.
Motor neuron degeneration in ALS has been correlated with
the presence of an uncontrolled inflammatory environment34,35
or with an inappropriate microglia activity, which impairs axonal
regeneration36,37. Our results point toward the importance of re-
educating microglia toward a homeostatic phenotype to reduce
motor neuron loss and identify NK cells as possible therapeutic
targets. While Treg and microglia modulation correlates
with disease progression in mutant SOD1 mice and ALS
patients3,21,30,38, we show that NK cell-mediated modulation of
these cell types only affects survival and onset time, possibly due
to specific or partial alteration of microglia or Treg phenotype in
the different experimental settings.
A new paradigm that emerged from our data is that motor
neuron degeneration results from direct cell-to-cell contacts with
NK cells, with mechanisms involving granule exocytosis and
perforin expression. A recent report on a model of peripheral
nerve injury, describes that the NKG2D ligand Rae1 is upregu-
lated in the lumbar DRG of adult mice upon cutting the corre-
sponding spinal nerve, and that neurite fragmentation is boosted
by IL-2 stimulated NK cells17. Our data that both in CNS tissue of
ALS patient and in hSOD1G93A mice, motor neurons express
different NKG2D ligands, identify NKG2D on NK cells as pos-
sible molecular targets to reduce motor neuron loss. Furthermore,
the observation that hSOD1G93A NK cells do not exert cytotoxic
activity toward wt motor neurons demonstrate that the kill-me
signal comes from mutant motor neurons.
Recent data identify Treg cells as suppressor of microglia
toxicity in mSOD39,38 mice; and ALS patient infusion with
expanded autologous Treg slows disease progression18. In addi-
tion to a direct neurotoxic activity of NK cells, we demonstrate an
IFNγ dependent recruitment of Foxp3+ Treg cells in the spinal
cord of hSOD1G93A mice, which could explain the positive effects
of NK cell depletion on mice survival29 and microglia pheno-
type9. The mechanisms of Treg and NK cells cross talk in
hSOD1G93A mice are not known, but could be mediated by
IFNγ38,39, since IFNγ blockade also increased foxp3 expression in
the spinal cord, or by TGFβ40. In contrast, NK cell depletion did
not alter CD4+ or CD8+ T cell infiltrate, although we cannot
exclude a possible cytotoxic role of CD8+ T cells in ALS41,42, also
as source of IFN-γ.
Altogether, our data support the critical role of innate immu-
nity in ALS-associated neurodegeneration and demonstrate the
neurotoxic properties of NK cells in the hSOD1G93A mice model.
Targeting NK cells could revert the vicious cycle among NK cells
(producing IFNγ) and neurons (producing CCL2), re-boosting
the homeostatic functions of microglia and sustaining Treg cell
recruitment in the spinal cord (see graphic summary in Fig. 8).
Together with the data obtained in ALS patients, our results point
to innate immunity as a key co-factor in this neurodegenerative
disease. It remains to be investigated whether a direct neurotoxic
role of NK cells could be relevant to other neurodegenerative
diseases.
Methods
Materials. All cell culture media, foetal bovine serum (FBS), goat serum, penicillin
G, streptomycin, Na pyruvate, glutamine, the Thermo Script RT-PCR System,
secondary Abs, and Hoechst (catalogue #33342, RRID:AB_10626776) were from
GIBCO Invitrogen (Carlsbad, CA, USA). Glucose, Percoll, Papain (#P3125),
phosphate buffered-saline (PBS) tablet (#P4417), Bovine Serum Albumine (BSA)
and deoxyribonuclease I, were from Sigma-Aldrich (Milan, Italy). Chloral hydrate
(#334085) was from Carlo Erba (Milan, Italy). NKp46 (M20) (#sc-18161, RRID:
AB_2149152) antibody (Ab) was from Santa Cruz biotechnology (Santa Cruz, CA).
ChAT (#AB144P) Ab was from Merck Millipore (Milan, Italy). BDNF was from
Immunological Sciences (Rome, Italy). IFNγ ELISA kit (KAC1231), and Mult-1 Ab
(Cat# 12-5863-81, RRID:AB 1210756) were from Life technologies Invitrogen
(Carlsbad, CA, USA). Microbeads CD11b+ were from Miltenyi Biotec (Bologna,
Fig. 3 NK cell–MN communication in ALS. a Expression of Mult-1 in the spinal cord of wt and hSOD1G93A mice (13 weeks) (n= 5). Scale bar: 20 μm.
b Colocalization of Smi32 and mult-1 covered area in spinal cord of wt and hSOD1G93A mice (n= 5 data are the mean ± s.e.m. **P < 0.01 power 1 two-tailed
Student’s t-test). For boxplots, the center line, boxes and whiskers represent the median, inner quartiles, and rest of the data distribution, respectively.
c RT-PCR of mult-1, rae-1, nectin-2 and pvr genes in NeuN+ cells sorted from lumbar spinal cord of wt and hSOD1G93A mice (13 weeks; n= 5, *P < 0.05,
**P < 0.01 power >0.85 vs wt mice, one-way ANOVA). d NK cells, isolated from the spleen of wt mice, were incubated with primary cultures of neurons
obtained from the spinal cord of wt or hSOD1G93A (13 weeks) mice (left), in the presence of a specific Ab against NKG2D, of dynasore, wiskostatin or
vehicle; degranulation of NK cells (having subtracted basal degranulation) in a 2.5:1 ratio with neurons was assessed by FACS analysis of CD107a+ cells
(middle panel); cell viability in neuron cultures is shown in the right panel (wt, n= 7. hSOD1G93A, vehicle n= 6, treated with AbNKG2D, dynasore and
wiskostatin n= 4, PRF−/− n= 4, **P < 0.01 power 0.999 one-way ANOVA). Error bars show mean ± SEM. e Representative image of NK cell—MN
contacts in the spinal cord of hSOD1G93A mice (original magnification, ×600). Scale bar: 20 μm. (hSOD1G93A mice, n= 6) f Quantification of MNs
(counted as Smi32+ cells in the ventral horns of the spinal cord) in wt (n= 5) and hSOD1G93A mice treated with vehicle (n= 6) or Ab-NK1.1 (n= 5), and
dendrimer or dendrimer-loaded with scrambled siRNA or siRNA-NKG2D41 (n= 4). Data are shown as mean ± s.e.m. **P < 0.01 power >0.9 one-way
ANOVA). Representative immunofluorescence images are shown on the right. Scale bar: 20 μm. Source data are provided as a Source Data file.
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Italy). RNeasy Mini Kit was from Qiagen (Hilden, Germany). CD45, CD69, CD3,
CD4, CD8, CD107a, CD133, NK1.1 Abs, and IL-15 were from eBioscience Inc.,
(San Diego, CA). Rabbit anti-Iba1 from Wako (Cat# 019-19741, RRID:AB_839504)
(VA, USA). Rat anti-IFNγ monoclonal antibody (clone: XMG1.2) (Cat# BE0055,
RRID:AB 1107694), anti-CCL2 (clone: 2H5) (Cat# BE0185, RRID:AB_10950302),
and anti-NK1.1 (Cat# BE0036, RRID:AB_1107737) were from Bioxcell (West
Lebanon, USA). ULBP-3 Ab (Cat# MAB1517, RRID:AB_2272829) was from R&D
systems (Minneapolis, MN, CANADA). Foxp3 Ab (Clone: FJK-16s) (Cat# 53-
5773-82, RRID:AB_763537) was from Thermo Fisher (San Diego, CA). CD31 Ab
(#3568 S, RRID:AB_10694616) was from Cell Signaling (WZ Leiden, The Neth-
erlands). SMI-32 Ab was from BioLegend (San Diego, CA). siRNA-NKG2D
ALEXA 488 (COD A10433) and scrambled siRNA were from Life technologies
Invitrogen (Carlsbad, CA, USA). Dendrimers were synthesized for siRNA delivery
as in43.
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Animals. Experiments described in the present work were approved by the Italian
Ministry of Health (authorization n. 78/2017-PR) in accordance with the guidelines
on the ethical use of animals from the European Community Council Directive of
September 22, 2010 (2010/63/EU), and from the Italian D.Leg 26/2014. All possible
efforts were made to minimize animal suffering, and to reduce the number of
animals used per condition by calculating the necessary sample size before per-
forming the experiments. Male and female hSOD1G93A [B6.Cg-Tg(SOD1-G93A)
1Gur/J line, the transgene copy number is typically 17-23] (RRID:
IMSR_JAX:004435), TDP43A315T [B6.Cg-Tg(Prnp-TARDBP*A315T)95Balo/J]
(Cat# JAX:010700, RRID:IMSR_JAX:010700), and C57BL/6-Prf1 < tm1Sdz > /J
(Cat# JAX:002407) transgenic mice were obtained from Jackson Laboratory (Bar
Harbor, ME, USA) and from Charles River (Calco, Italy). hSOD1G93A were also
maintained as hemizygotes by breeding transgenic males with wild-type C57BL/6 J
females from Charles River Laboratories, both maintained on C57BL/6 J genetic
background. Age-matched non-transgenic C57BL/6 J mice were always used as
controls. Transgenic mice were identified by PCR on DNA obtained from tail
biopsies. Briefly, tail tips were digested (overnight, 58 °C) in a buffer containing
100 mM Tris–HCl pH 8, 0.1% SDS 20, 5 mM EDTA pH 8, 200 mM NaCl and
20 mg/ml proteinase K (Ambion-Thermo Fisher, Germany, #2548) and the
genomic DNA was amplified with SsoFast Eva Green Supermix (Bio-Rad, Cali-
fornia, #172-5201) using the following primers: SOD1 forward 5′-CATCAGCCC
TAATCCATCTGA-3′; SOD1 reverse 5′- CGCGACTAACAATCAAAGTGA-3′.
Mice were housed in standard breeding cages at a constant temperature (22 ± 1 °C)
and relative humidity (50%), with a 12:12 h light:dark cycle (light on 07.00–19.00 h).
Food and water were available ad libitum. Microbiological analyses were routinely
(each 3–4 months) performed and defined endemic Norovirus and Helicobacter in
our conventional animal facility. Mice were evaluated for motor deficits with a
behavioural score system: 0= Full extension of hind legs away from the lateral
midline when the mouse is suspended by tail; the mouse must hold this position for
2 s, and is suspended 2–3 times; 1= Collapse or partial collapse of leg extension
towards lateral midline (weakness) or trembling of hind legs during tail suspension;
2= Curling of the toes and dragging of at least one limb during walking; 3= Rigid
paralysis or minimal joint movement; foot not used for forward motion; 4=Mouse
cannot stand up in 20 s from either side, euthanasia.
Patients enrolment. We studied 15 patients with sporadic (mean age 61.3 ±
5.2 years), probable (clinically or laboratory supported) or definite ALS44, recruited
from the Rare Neuromuscular Diseases Centre of Umberto I Hospital in Rome (ref
3314/25.09.14, protocol n. 1186/14). The study was conducted according to the
declaration of Helsinki and was approved by the institutional ethics committee.
Informed consent was obtained from all the subjects. Patients were evaluated using
the ALS Functional Rating Scale-Revised (ALSFRS-R), the Medical Research
Council (MRC) score. All patients took Riluzole 50 mg BID. Healthy Donors
stratified for age and sex were also enrolled as control. Table 2 resume the char-
acteristics of ALS patients and healthy donors enrolled in the study.
Human brain and spinal cord tissues. Postmortem material was obtained at
autopsy from 12 ALS patients at the department of (Neuro)Pathology of the
Amsterdam UMC, Academic Medical Center, (University of Amsterdam, the
Netherlands). All patients fulfilled the diagnostic criteria for ALS (El Escorial cri-
teria45) as reviewed independently by two neuropathologists. All patients with ALS
died from respiratory failure. Control spinal cord tissue was obtained from eight
patients who had died from a non-neurological disease. Both ALS and control
patients included in the study displayed no signs of infection before death.
Informed consent was obtained for the use of brain tissue and for access to medical
records for research purposes and approval was obtained from the relevant local
ethical committees for medical research. All autopsies were performed within 10
hours after death. ALS sporadic patients did not showed mutation for SOD or FUS
proteins. Four patients were positive for the C9ORF72 hexanucleotide repeat
expansion.
Table 1 resume the characteristics of ALS patients and control enrolled in
the study.
Tissue preparation: paraffin-embedded tissue was sectioned at 6 µm and
mounted on pre-coated glass slides (StarFrost, Waldemar Knittel Glasbearbeitungs
GmbH, Braunschweig, Germany). Representative sections of all specimens were
processed for haematoxylin and eosin, Klüver-Barrera and Nissl stains.
Primary spinal cord neurons culture from adult mice. Neurons cultures were
obtained from spinal cord 13w C57BL6/J or hSODG93A mice. Mice were eutha-
nized by cervical dislocation and the spinal cords were removed; tissues were
digested with 30U/ml papain at 37 °C. After 20 min the reaction was stopped by
adding papain inhibitor and pipetting 10–15 times with a glass Pasteur pipette,
until no more cell aggregates were visible. Cells were filtered with 100μm cell-
strainer and centrifuged at 300 × g for 8 min. The pellet was resuspended in
complete Neurobasal medium (Gibco, part of Thermo Fisher, Germany #10888-
022) (2 mM glutamine, 1% B27, 100 U/ml penicillin and 0.1 mg/mL streptomycin,
BDNF 10 ng/ml) and plated (2 × 105 cells/well) onto poly-L-lysine coated glass
cover slips. After 14 days in culture, purity of neuronal cells (analysed as Smi32+
cells) ranges between 50 and 60%.
Immunofluorescence and FACS analysis. Immune cells from wt or hSODG93A
mice were enriched by centrifugation on percoll 40%, washed in PBS and immu-
nostained with fluorochrome-conjugated anti-CD3, anti-NK1.1, anti-CD19 and
anti-CD45.2 to identify T cells (CD3+NK1.1−) NK cells (NK1.1+CD3−) and B
cells (CD19+) and analyzed by flow cytometry using a FACSCanto II (BD Bios-
ciences). Data were elaborated using FlowJo Version 9.3.2 software (TreeStar).
NK cells purification from blood patients. Peripheral blood mononuclear cells
(PBMCs), freshly isolated by lymphoprep (Nycomed AS, Oslo, Norway) were
frozen and stored at −80 °C for up to 2 months. The day before the experiment,
cells were thawed and kept in culture O/N for recovering. Then, death cells were
removed, and cells were stained with NK cell subset specific antibodies or were
used for functional assays. To determine NK cell degranulation potential, PBMCs
were co-cultured with K562 cells at 1:1 effector/target ratio for 3 h in complete
RPMI 1640 medium (Hepes 10 mM+ Monensin 100 μM), and degranulation was
assessed by evaluation of the lysosomal marker CD107a expression on CD56+
CD3− cells by FACS analysis. To determine intracellular IFNγ production, cells
were maintained in culture for 6 h in the presence of Brefeldine A (10 µg/ml),
stained with anti-CD56 and -CD3 and subsequently fixed and permeabilized using
Cytofix/cytoperm kit (BD Biosciences). After permeabilization, cells were stained
with anti-IFN-γ specific mAb and analyzed by FACS.
Mice treatment. Starting at 8 weeks of age, male and female hSOD1G93A,
TDP43A315T or non-transgenic C57BL/6 J mice were randomly grouped for the
treatments. NK cell depletion was performed using a blocking Ab against NK1.1,
which recognizes an epitope of the NKR1Pc-activating receptor (PK136). Mice
were i.p. injected with 200 μg (in 100 μl) of anti-NK1.1 Ab every 2 days the first
week, every 4 days the second week and then repeated once a week until the age
described in the text or until sacrifice for the survival analysis experiments. NK cell
depletion from the blood sample was monitored by FACS16,23. For Ab anti-IFNγ
treatment, mice were treated with 200 μg of rat XMG1.2, or control Ab isotype, by
i.p. injection repeated every 5 days until the mice were sacrificed. For Ab anti-CCL2
administration, mice were i.p. treated with 200μg, every 4 days until the age
described in the text or until sacrifice. Control mice were treated with the corre-
sponding control IgG.
Survival analysis. hSOD1G93A and TDP43A315T mice were treated with Ab anti-
NK1.1, XMG1.2 or vehicle as described above and were monitored daily. The
endpoint was fixed when animals were unable to stand up within 20 s after being
placed on either side, or death. The probability of survival was calculated using the
Kaplan–Meier method, and statistical analyses were performed using a log-
rank test.
Behavioural tests. Behavioural tests started when mice were 8-week-old. All
animals were handled for at least 5 min/day for 2–3 days before starting the
experiments. For the hindlimb extension reflex, mice were suspended by the tail,
and scored for hindlimb extension reflex deficits. The scores were recorded from 0
to 2 as follows: 2, normal extension reflex in both hind limbs; 1.5, imbalanced
extension in the hind limbs; 1.0, extension reflex in only one hindlimb; 0.5, the
absence of any hindlimb extension; and 0, total paralysis. For the inverted grid test
mice were placed in the center of a wire grid (40 × 60 cm, suspended 50 cm above a
Fig. 4 NK cells modulate microglia phenotype in hSOD1G93A mice. a Quantification of soma and scanning domain area, branch numbers and length of
Iba1+ cells in slices obtained from the spinal cord of wt and hSOD1G93A mice (13 weeks) treated with vehicle or Ab-NK1.1. Right: representative images
(original magnification, ×600; Scale bar: 10 μm) of the maximal intensity projections of confocal z-stack images of Iba1+ cells in the different conditions,
converted to binary images and then skeletonized. (n= 3 mice per treatment, 30 cells per mice in at least six slices. **P < 0.01 power 0.921 one-way
ANOVA). Error bars show mean ± SEM. b Mean (±s.e.m.) area of Iba1+ cells (expressed as % of spinal cord area) in wt or hSOD1G93A mice (13 weeks)
treated with vehicle or Ab-NK1.1 (n= 4, **P < 0.01 power 1 one-way ANOVA). Right: representative immunofluorescence image of Iba1+ cells in spinal cord
sections. Scale bar: 50 μm. c–g RT-PCR of il-6, il-1β, tnfα, nos2, nox2, p47phox, chil3, socs3, arg-1, tgfb, msod1, p2yr12, trem2, kcnn4, bdnf, il-15 gene expression
in microglial cells isolated from the lumbar spinal cord of wt or hSOD1G93A mice (13 weeks) treated with vehicle or Ab-NK1.1 (n= 5 mice. Data are the
mean ± s.e.m. *P < 0.05 **P < 0.01 power >0.85 one-way ANOVA). Source data are provided as a Source Data file.
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cushioned table) and then the grid was inverted (maximum time allowed 60 s). The
time spent hanging on to the grid was measured. For the Rotarod test, motor
coordination, strength and balance were assessed using a rotarod apparatus (Ugo
Basile, Gemonio Italy, #47650). Animals were placed onto the cylinder at a con-
stant speed of 15 rpm. The arbitrary cut-off time was 300 s., and the longest latency
was recorded. For the hanging wire test mice were allowed to grab a horizontal wire
with their front paws and the time spent hanging measured (maximum time
allowed 60 s). Behaviour was scored according to the following scale: 1, hanging
onto the bar with both forepaws; 2, in addition to 1, attempted to climb onto the
bar; 3, hanging onto the bar with two forepaws and one or both hindpaws; 4,
hanging onto the bar with all four paws with tail wrapped around the bar; 5, able to
walk on the bar to escape.
Immunostaining. In different stages of pathology, mice were overdosed with
chloral hydrate (400 mg/kg, i.p.) and then intra-cardially perfused with PBS and
then PFA 4%; brains and spinal cord were then isolated, fixed in 4% formaldehyde
and snap frozen. Cryostat sections (20 μm) were washed in PBS, blocked (3% goat
serum in 0.3% Triton X-100) for 1 h, at RT, and incubated overnight at 4 °C with
specific antibodies diluted in PBS containing 1% goat serum and 0.1% Triton
X-100. The sections were incubated with the following primary Abs: anti-NKp46
(1:50), anti-CD31 (1:200), anti-Smi32 (1:500), anti-ChAT (1:100), anti-Mult-1
(1:100), anti-Foxp3 (1:100) and anti-Iba1 (1:500). For immunostaining on paraffin-
embedded human motor cortex section, tissues were placed at 60 °C for 15 min,
incubated in xylene at RT for 25 min, and then transferred sequentially into 100%
EtOH, 95% EtOH, 70% EtOH, and 50% EtOH for 4 min at RT. The sections were
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rinsed in deionized water and incubated with Abs: anti-Smi32 (1:500), anti-NKp46
(1:50) and anti-ULBP3 (1:100). After several washes, sections were stained with the
fluorophore-conjugated antibody and Hoechst for nuclei visualization and analysed
using a fluorescence microscope. For co-immunofluorescence, the secondary
antibody was subsequently used. For Iba1 and Smi32 staining, coronal sections
were first boiled for 20 min in citrate buffer (pH 6.0) at 95–100 °C.
Motor neuron survival evaluation. For MN survival, the whole ventral horns of
lumbar spinal cord were photographed at ×20 magnification and digitized using a
CoolSNAP camera (Photometrics) coupled to an ECLIPSE Ti-S microscope
(Nikon) and processed using MetaMorph 7.6.5.0 image analysis software (Mole-
cular Device). The number of MNs was evaluated counting only Smi32-positive
cells with typical morphology triangular shape, single well-defined axon, large body
diameter (≥20 μm) and intact axons and dendrites. This analysis was done in at
least 12 serial slices for each animal.
Isolation of NeuN-positive cells and extraction of total RNA. The isolated
spinal cords were cut in small pieces and single-cell suspension was achieved by
enzymatic digestion in trypsin (0.25 mg/ml) solution in HBSS. The tissue was
further mechanically dissociated using a wide-tipped glass pipette and the sus-
pension applied to a 70 μm nylon cell strainer. Cells, obtained after a three-step
Percoll gradient45,46 were stained with anti-NeuN Ab (1:1000) at 4 °C for 30 min
and isolated using a FACSAria II (BD Biosciences). Cell purity was at least 94%, as
verified by flow cytometry and PCR analysis47. After cell sorting, total RNA was
isolated by RNeasy Mini Kit and processed for real-time PCR.
Isolation of lumbar microglia cells. Adult microglia were isolated from the
lumbar spinal cord tract of age-matched non-transgenic C57BL/6 J wt mice and
hSOD1G93A mice48. In detail, mice were deeply anesthetized with chloral hydrate
(i.p., 400 mg/Kg) before being transcardially perfused with PBS. Spinal cords were
then flushed out from the spinal canal using a 20 ml syringe filled with PBS and
digested with 30 units of papain (15–23 U/mg protein) for 30 min at 37 °C. Tissue
was then triturated with a pipette to obtain single-cell suspensions, which were
applied to 70 μm/40 μm cell strainers and used for the experiments. Purity of
isolated microglia cells ranges between 70 and 90%, and were selected only the
samples in which the purity was 90%.
Real-time PCR. Microglial cells and NeuN+ cells sorted from spinal cord of mice
were lysed in Trizol reagent for isolation of RNA. Reverse transcription reaction
was performed in a thermocycler (MJ Mini Personal Thermal Cycler; Biorad) using
IScript TM Reverse Transcription Supermix (Biorad) according to the manu-
facturer’s protocol, under the following conditions: incubation at 25 °C for 5 min,
reverse transcription at 42 °C for 30 min, inactivation at 85 °C for 5 min. Real-time
PCR (RT-PCR) was carried out in a I-Cycler IQ Multicolor RT-PCR Detection
System (Biorad) using SsoFast EvaGreen Supermix (Biorad) according to the
manufacturer’s instructions. The PCR protocol consisted of 40 cycles of dena-
turation at 95 °C for 30 s and annealing/extension at 60 °C for 30 s. For quantifi-
cation analysis, the comparative Threshold Cycle (Ct) method was used. The Ct
values from each gene were normalized to the Ct value of GAPDH in the same
RNA samples. Relative quantification was performed using the 2ΔDDCt method49
and expressed as fold change in arbitrary values. The primers used were listed in
Supplementary Table 1.
Cytotoxicity and degranulation assays. Cell viability of spinal cord primary
culture was determined by MTT assay or by staining dead cells50. Results are
expressed as percentage of cell survival, taking as 100% the cells not incubated
with NK cells. In order to analyse NK cell degranulation, purified NK cells were
activated O/N in IL-15 (50 ng/ml) and then co-incubated with MNs or GL261
for 4 h at the Effector:Target (E:T) ratios indicated in Fig. 3d and Supplementary
Figs. 3 and 4. The last two hours, FITC-conjugated anti-mouse CD107a or IgG
were added directly into each well. NK cells were collected from the non-
adherent fraction and analysed by FACS. Cell viability of spinal cord primary
culture was determined by MTT assay or by staining dead cells. Results are
expressed as percentage of cell survival, taking as 100% the cells not incubated with
NK cells.
Morphological analysis of Iba1+ cells and 3D reconstruction. Brain and lumbar
spinal cord slices from perfused mice were analysed by confocal microscopy and
skeleton analysis to assess Iba1+ cell morphology. Twenty mm z-stacks were
acquired at 0.5 mm intervals using an FV1000 laser scanning microscope (Olym-
pus) at ×60 objective. Maximal intensity projections of each image were generated,
binarized, and skeletonized using the Skeletonize 2D/3D plugin in ImageJ, after
which the Analyze Skeleton plugin (http://imagej.net/AnalyzeSkeleton) was
applied. The average branch number (process end points per cell) and length
per cell were recorded for each image with a voxel size exclusion limit of 150
applied. The number of single and multiple junction points was additionally
Fig. 5 IFNγ mediates the effects of NK cells in ALS. a Expression of IFNγ in the spinal cord of wt or hSOD1G93A mice (13 weeks) treated with control IgG
or Ab-NK1.1 (n= 5, **P < 0.01 power 1 one-way ANOVA). Error bars show mean ± SEM. b Frequency of IFNγ+/NK1.1+/CD3− cell population isolated from
the spinal cord of hSOD1G93A mice (n= 5). Representative FACS analysis is shown on the right. c Scheme of mice treatment with XMG1.2. d Kaplan–Meier
curve of hSOD1G93A mice treated with control IgG or XMG1.2 (hSOD1G93A n= 7 vehicle: 138.7 ± 2.5 days; n= 6 XMG1.2: 149.7 ± 2.3 days, data are the
mean ± s.e.m. **P < 0.01 two-sided log-rank test). e Age of paralysis, considered as the absence of hindlimb movement, upon XMG1.2 treatment, in
hSOD1G93A mice (n= 7 vehicle: 18.6 ± 0.3 weeks; n= 6 XMG1.2: 20.0 ± 0.3 weeks. Data are the mean ± s.e.m. **P < 0.01 power 0.80 one-way ANOVA).
RT-PCR analysis of il-6, il-1β, tnfα, nos2 (f); and bdnf, chil3, socs3, arg-1 (g) gene expression in microglial cells isolated from the lumbar spinal cord of wt or
hSOD1G93A mice (13 weeks) treated with control IgG or XMG1.2 (n= 5. Data are the mean ± s.e.m. wt vs hSOD1G93A and hSOD1G93A vs hSOD1G93A –
XMG1.2. *P < 0.05 **P < 0.01 power >0.9 one-way ANOVA). h RT-PCR of ccl2 expression in NeuN+ cells isolated from the lumbar spinal cord of wt and
hSOD1G93A mice (13 weeks) treated with control IgG, Ab-NK1.1 or XMG1.2 (n= 5, **P < 0.01 power 0.859 vs wt mice, one-way ANOVA). i RT-PCR of ccl2
expression in microglia isolated from the lumbar spinal cord of wt and hSOD1G93A mice (13 weeks) treated with control IgG or Ab-NK1.1 (n= 5, **P < 0.01
power 0.859 vs wt mice, one-way ANOVA). Each dot (h, i) represents the qPCR analysis of ccl2 per mice. Source data are provided as a Source Data file.
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calculated to give an indication of branching complexity. The areas of the soma
and scanning domain were measured for each cell. 3D reconstruction of NK
cells was achieved by confocal microscopy analysis with a FV1200 (Olympus)
Laser Scanning System, at ×60 magnification. NK cells were identified with an
Alexa fluor 594 conjugated NKp46 antibody. Acquisition files were then
processed with ImageJ software for two-dimensional analysis. Three-dimensional
reconstructions were generated with Imaris software (Bitplane, Zurich,
Switzerland).
Image acquisition and data analysis. Images were digitized using a CoolSNAP
camera (Photometrics) coupled to an ECLIPSE Ti-S microscope (Nikon) and
processed using MetaMorph 7.6.5.0 image analysis software (Molecular Device).
Slices were scanned by consecutive fields of vision (×10 objective lens) to build a
single image per section. Data were expressed as area occupied by fluorescent cells
versus total area by converting pixel to mm. For comparison between different
treatments, at least 12 coronal sections per lumbar spinal cord or brain were
analysed.
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Measurement of IFNγ by ELISA. The spinal cord of control and sALS
patients, or 13-weeks-wt and hSOD1G93A mice were disrupted with a homo-
genizer and analysed for IFNγ content using a sandwich ELISA, following the
manufacturer’s instructions. Briefly, 96-well ELISA microplates were coated with
anti- IFNγ monoclonal Ab. Samples or IFNγ standard were added at the
appropriate dilution and incubated for 2 h at room temperature. After careful
washing, biotinylated goat anti-human IFNγ was added to each well;
horseradish-peroxidase was used as secondary Ab and optical density was read at
450 nm.
Statistical analysis. Data are shown as the mean ± SEM. Statistical significance
was assessed by Student’s t-test, one-way ANOVA or two-way ANOVA for
parametrical data, as indicated; Holm–Sidak test was used as a post-hoc test;
Mann–Whitney Rank test and Kruskal–Wallis for non-parametrical data, follo-
wed by Dunn’s or Tukey’s post-hoc tests. For multiple comparisons, multiplicity-
adjusted p-values are indicated in the corresponding figures (*p < 0.05, **p < 0.01).
Power calculation (power) was added in all the figure legends. For the Kaplan–
Meier analysis of survival, the log-rank test was used. Statistical analyses com-
prising calculation of degrees of freedom were done using Sigma Plot 11.0, Imaris;
Origin 7, and Prism 7 software.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
author upon reasonable request. The source data are provided as a Source Data file.
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